Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.

Antiviral research - 1 Jul 2017

Cox Stephanie, Margot Nicolas, Ram Renee, Johnson Audun, Miller Michael, Callebaut Christian

Abstract excerpt

Resistance selection experiments using HIV-1 isolates harboring pre-existing tenofovir (TFV)-resistance (K65R, 3TAMs, and Q151M complex) were carried out with the novel tenofovir prodrug tenofovir alafenamide (TAF) as well as with tenofovir (TFV), to investigate the potential for additional resistance development in the presence of TAF or TFV. Extended resistance selection of these TFV resistance associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Viral

Share to HEK293 Cells

Share to Prodrugs

Share to Tenofovir

Source

Identifiers

PMID: 28363735
DOI: 10.1016/j.antiviral.2017.03.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.PMID 28363735Read ↗

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Semantic proximity Read ↗

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.Semantic proximity Read ↗

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic.Semantic proximity Read ↗

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.Semantic proximity Read ↗

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.Semantic proximity Read ↗

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Semantic proximity Read ↗

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing RegimensSemantic proximity Read ↗

First Report of Tenofovir Alafenamide Treatment Failure in Chronic Hepatitis B with Detection of Putative Tenofovir Resistance MutationsSemantic proximity Read ↗

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.Semantic proximity Read ↗

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.